FDA prepares to approve Perjeta for use pre-surgery
The Food and Drug Administration’s (FDA) advisory committee cleared the way for the approval of pertuzumab (Perjeta) to treat patients before they have surgery to remove their HER2-positive tumors. If approved, pertuzumab would be the first neoadjuvant drug approval for any form of cancer. The drug was already approved by the FDA for treatment of late-stage breast cancer last year.
The Food and Drug Administration’s (FDA) advisory committee cleared the way for the approval of pertuzumab (Perjeta) to treat patients before they have surgery to remove their HER2-positive tumors. If approved, pertuzumab would be the first neoadjuvant drug approval for any form of cancer. The drug was already approved by the FDA for treatment of late-stage breast cancer last year.
The drug would be used only on a minority of patients, particularly those with large tumors or other serious risk factors. According to the drug’s manufacturer, it would be indicated account for roughly 15,000 women out of the 220,000 new cases of early-stage breast cancer.
The recommendation was based on 2 Phase II studies of pertuzumab in high-risk, HER2-positive early-stage breast cancer. A Phase III study evaluating the effectiveness of the drug after surgery is ongoing, with data expected in 2016.
Some of the committee’s members expressed concern over potential cardiac effects of the drug.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.
Exogenous hormones and patients at increased risk for breast cancer
October 17th 2023This lecture, presented by Holly J. Pederson, MD, at The Menopause Society 2023 Annual Meeting, looked at combined oral contraceptives in BRCA carriers and other high-risk patients, and hormone therapy in postmenopausal gene carriers as well as other high-risk women.
Read More
Hormone replacement therapy does not increase breast cancer recurrence, mortality in survivors
July 20th 2022An analysis of data from more than 8400 postmenopausal women with a history of early-stage nonmetastatic, ER-positive breast cancer suggests there was no increase in risk of breast cancer recurrence or mortality observed with use of vaginal estrogen therapy or menopausal hormone therapy.
Read More
